
Caregivers reported itch, symptom, and QOL gains with roflumilast cream 0.05% in infants with AD; an FDA decision is due February 2027.
Valuable as they are, available vaccines have limitations, which keeps the search for new ones going. Here is a preview of what to look forward to in this corner of therapeutics.






